| Document |
Document Title |
|
WO/2020/151500A1 |
Disclosed herein are an organic electroluminescent compound, an electroluminescent material and an organic electroluminescent component. The organic electroluminescent compound has the structure of formula (1). The organic electrolumines...
|
|
WO/2020/147738A1 |
The present subject matter relates to fluorescent compounds that have aggregation-induced emission (AIE) characteristics and tunable emission colors. The emission range of these compounds covers the whole visible region and extends to th...
|
|
WO/2020/150417A2 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2020/149710A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element including a first electrode, a second electrode, and an organic layer formed between the first electrode and the second electrode...
|
|
WO/2020/144695A1 |
Disclosed herein are compounds comprising an electrophilic moiety and rigid moiety for use in modulating an activity of Pin 1. The rigid moiety comprises at least one functional group that is capable of forming hydrogen bonds with hydrog...
|
|
WO/2020/140894A1 |
The present invention relates to fluorine-containing substituted benzothiophene compound, and a pharmaceutical composition and an application thereof. Specifically, the compound of the present invention has the structure as shown in form...
|
|
WO/2020/130528A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting diode comprising same.
|
|
WO/2020/130327A1 |
The present invention provides a novel compound and an organic light-emitting device using same.
|
|
WO/2020/130511A1 |
The present specification pertains to: a compound of chemical formula 1; and an organic light-emitting device including same.
|
|
WO/2020/127259A2 |
The present application concerns compounds for use in electronic devices, processes for preparing the compounds, and electronic devices comprising the compounds.
|
|
WO/2020/127960A1 |
The present invention relates to disubstituted alkyne derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.
|
|
WO/2020/127176A1 |
The present application concerns compounds for use in electronic devices, processes for preparing the compounds, and electronic devices comprising the compounds.
|
|
WO/2020/130623A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/121823A1 |
The present invention addresses the problem of providing: a liquid crystal composition which is to be used in an active drive display element and improves chromatic dispersion properties; a display element which uses said liquid crystal ...
|
|
WO/2020/116816A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic layer placed between the first and second electrodes; and an elect...
|
|
WO/2020/108538A1 |
An RORγ inhibitor having sulfonyl structure, a preparation method thereof, and a pharmaceutical composition containing a plurality of compounds. The inhibitor has a structure represented by formula (I) or formula (V), wherein the compou...
|
|
WO/2020/112390A1 |
Disclosed are compounds of Formula (1), N-oxides, and salts thereof, wherein Q, X, Y, A1, A2, L, R1, R2, R3, R4, R5, R6a, R6b, R7 and R8 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formul...
|
|
WO/2020/106305A1 |
Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject...
|
|
WO/2020/102889A1 |
The invention encompasses the novel class of compounds represented by the Formula (I), (II), (III) and (IV) below, which are modulators of RORγt:. The invention also encompasses pharmaceutical compositions which include the compounds sh...
|
|
WO/2020/104657A1 |
The present application relates to compounds with NLRP3inhibitory activity and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present application further relates to the use of such compounds in the treatment...
|
|
WO/2020/102576A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/102574A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/094542A1 |
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...
|
|
WO/2020/095983A1 |
It was discovered that a cyclic sulfamidate could be produced by reacting an aminoacid derivative with a cyclization reagent. In addition, it was discovered that an O-substituted serine derivative could be produced by reacting the cyclic...
|
|
WO/2020/096001A1 |
A compound represented by formula (1) (wherein R1 to R8, R10 to R19, R30 to R46, Ar, L, and *a are as defined in the description) is useful in providing an organic EL element having improved element performance.
|
|
WO/2020/093286A1 |
A non-fused electron acceptor material, a preparation method and an organic solar cell constructed using same. The organic solar cell comprises a substrate, a negative electrode, an electron transport layer, an active layer, a positive e...
|
|
WO/2020/095031A1 |
Organosulfur compounds of formula (I), where R1 and R2 are as defined herein, and pharmaceutical compositions comprising these organosulfur compounds. Uses of the organosulfur compounds and the pharmaceutical compositions for treating in...
|
|
WO/2020/090843A1 |
A charge transport material which is represented by general formula (1). In the formula, one of R1-R5 moieties represents a cyano group, while two to four of the R1-R5 moieties represent a group represented by general formula (2); X repr...
|
|
WO/2020/091446A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. By comprising the organic electroluminescent compound according to the present disclosure, an organic ...
|
|
WO/2020/087233A1 |
Disclosed is an application of an ionic iron (III) complex as a catalyst in preparation of a benzylamine compound, that is, an ionic iron (III) complex having a molecular formula of [(RNCHCHNR)CH][FeBr4] (R is tert-butyl) and containing ...
|
|
WO/2020/089138A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, to a process for manufacturing the compounds of formula (1), to intermediat...
|
|
WO/2020/092239A1 |
Provided herein are processes for the preparation of N1,N3-dialkylated thienopyrimidinediones that are useful as fungicides, and related precursors and intermediates.
|
|
WO/2020/085396A1 |
A cross-coupling reaction method including: preparation of an aromatic compound (1) that has a leaving group; preparation of a compound (2) capable of a cross-coupling reaction, the compound (2) being selected from aromatic amino compoun...
|
|
WO/2020/086728A1 |
In one aspect, compounds of Formula A, or a pharmaceutically acceptable salt thereof, are featured (Formula A) or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/085797A1 |
The present invention relates to a compound for an organic electric element, an organic electric element using same, and an electronic device thereof. According to the present invention, high light-emitting efficiency, low driving voltag...
|
|
WO/2020/084094A1 |
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...
|
|
WO/2020/083327A1 |
Disclosed in the present invention is an organic compound containing a spirobifluorene structure, having a structure as represented by chemical formula (1), wherein Ar1(Ar2)N-(S1)m- and -(S2)n-NAr3(Ar4) are different, and have symmetrica...
|
|
WO/2020/086732A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/082817A1 |
The present application pertains to the technical field of pharmaceutical compounds and drugs, relates to an oxime-based naphthoquinone compound, a preparation method therefor and the uses thereof, and specifically relates to a formula (...
|
|
WO/2020/078368A1 |
An organic phosphorus compound, a preparation method therefor, and the uses thereof. The organic phosphorus compound exhibits significant bearing capacity, and excellent antiwear and wear reduction properties, while being an EP antiwear ...
|
|
WO/2020/081446A1 |
Embodiments are directed to a series of novel small molecule activators of NRF2 dependent gene expression that are evaluated in an effort to develop therapeutic methods against diseases with deregulated KEAP1-NRF2 signaling.
|
|
WO/2020/080979A1 |
This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, me...
|
|
WO/2020/076035A1 |
The present invention provides a thiophene carboxamide compound of the following general formula (I), which is a novel fluorine-substituted biphenyl carboxamide-based compound, and provides a useful compound, as an agricultural and horti...
|
|
WO/2020/075964A1 |
The present invention provides a novel compound and an organic light emitting diode using same.
|
|
WO/2020/073031A1 |
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to nicotinamide phosphoribosyltransferase (NAM FT) expression. More part...
|
|
WO/2020/071550A1 |
The present invention provides a novel CDK8 inhibitor. The present invention relates to: a compound represented by general formula (I) (wherein the symbols are as defined in the description) or a pharmaceutically acceptable salt thereof;...
|
|
WO/2020/065642A1 |
The present invention provides new GABAA receptor-binding compounds that modify the activation of GABAA, their use in in the preparation of a neuroactive pharmaceutical composition, improving sperm motility and labeling of biomolecules.
|
|
WO/2020/065119A1 |
The invention relates to a group of compounds with a structural nucleus of acylhydrazone, which are capable of modulating the interaction between the proteins NCS-1 and Ric8a involved in the process of regulating the number of synapses a...
|
|
WO/2020/054420A1 |
A fluorine-containing ether compound represented by formula (1) (1: R1-R2-CH2-R3-CH2-R4) (In formula (1), R1 is represented by formula (2), R2 is represented by formula (3), R3 is a perfluoropolyether chain, and R4 is an organic end grou...
|
|
WO/2020/055883A1 |
The present disclosure provides certain 2,3-dihydrobenzo[b]thiophene compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also pro...
|
